The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease

OBJECTIVE: Sodium glucose co-transporter 2 inhibitor (SGLT-2i), recommended for patients with type 2 diabetes, has been reported to improve the liver function test results in non-alcoholic fatty liver disease (NAFLD). However, the long-term effects of SGLT-2i on the liver function and body weight in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashima, Mio, Miyaaki, Hisamitsu, Miuma, Satoshi, Shibata, Hidetaka, Sasaki, Ryu, Haraguchi, Masafumi, Fukushima, Masanori, Nakao, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702010/
https://www.ncbi.nlm.nih.gov/pubmed/31308341
http://dx.doi.org/10.2169/internalmedicine.2566-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702010/
https://www.ncbi.nlm.nih.gov/pubmed/31308341
http://dx.doi.org/10.2169/internalmedicine.2566-18

Ejemplares similares